Arvinas (ARVN) vs Zevra Therapeutics (ZVRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Zevra Therapeutics (ZVRA) has outperformed Arvinas (ARVN) over the past year, losing 8.0% versus a loss of 26.8%. Over five years, ZVRA leads with a -1.5% price change compared with -91.8% for ARVN. Zevra Therapeutics is the larger company by market cap ($590.3 million vs $449.7 million), about 1.3 times the size.
On valuation, Zevra Therapeutics trades at a lower trailing P/E (10.8x vs 26.8x for Arvinas). Zevra Therapeutics converts more of its revenue into profit, with a net margin of 78.2% versus -30.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARVN | ZVRA |
|---|---|---|
| Share price | $6.97 | $9.94 |
| Market cap | $449.71M | $590.27M |
| 1-day change | -2.65% | -3.21% |
| YTD return | -41.23% | +10.94% |
| 1-year return | -26.79% | -8.01% |
| 5-year return | -91.79% | -1.49% |
| P/E ratio (TTM) | 26.81 | 10.80 |
| Forward P/E | — | 9.23 |
| EPS (TTM) | $0.26 | $0.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $262.60M | $106.47M |
| Revenue growth (YoY) | -0.30% | +350.91% |
| Net income (latest FY) | $-80.80M | $83.23M |
| Gross margin | — | 84.52% |
| Operating margin | -45.13% | -59.12% |
| Net margin | -30.77% | 78.17% |
| 52-week high | $14.51 | $15.04 |
| 52-week low | $6.74 | $8.01 |
| Distance from 52-week high | -51.96% | -33.89% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +99.86% | +151.51% |
| Average volume | 800.32K | 1.07M |
| Shares outstanding | 64.52M | 59.38M |
| Employees | 246 | 61 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZVRA has outperformed ARVN by 18.8 percentage points over the past year.
- Arvinas trades at a higher earnings multiple (26.8x vs 10.8x trailing P/E).
- Zevra Therapeutics is more profitable, keeping 78.2 cents of every revenue dollar as net income versus -30.8 cents for Arvinas.
- Zevra Therapeutics grew revenue faster in its latest fiscal year (+350.91% vs -0.30%).
About Arvinas
ARVN stock →Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
Healthcare · Biotechnology · 246 employees
About Zevra Therapeutics
ZVRA stock →Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform.
Healthcare · Biotechnology · 61 employees
ARVN vs ZVRA FAQ
Which is bigger, Arvinas or Zevra Therapeutics?
Zevra Therapeutics (ZVRA) is larger, with a market capitalization of $590.27M compared with $449.71M for Arvinas (ARVN).
Which stock has performed better over the past year, ARVN or ZVRA?
ZVRA returned -8.01% over the past 12 months, compared with -26.79% for ARVN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ARVN or ZVRA?
ZVRA has the lower trailing P/E at 10.8, versus 26.8 for ARVN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Arvinas and Zevra Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.